Thank you very much. I won't read the amendment. I'll just give the explanation.
First of all, we should explicitly state that the results of clinical trials are not proprietary and should be publicly disclosed, including things like de-identified patient-level data, post-market studies, and adverse drug reactions reported by drug manufacturers and health care institutions, which are covered under the term “clinical trials and investigational tests”. We believe this amendment will actually make sure that those results are not proprietary and are made public.